Post by Grünenthal Group

Our investigational compound tegacorat received Orphan Drug and Rare Pediatric Disease designations from the US FDA for the treatment of Duchenne muscular dystrophy (DMD). The Selective Glucocorticoid Receptor Agonist and Modulator is designed to influence glucocorticoid receptor activity in a way that emphasises anti-inflammatory pathways while reducing activation of downstream pathways associated with metabolic and growth-related side effects. While this has not yet been established in clinical trials, it may allow for more efficacious dosing than current standard treatments and potentially cause fewer side effects. Grünenthal is developing tegacorat as an alternative to glucocorticoid-based treatments such as prednisone, the current standard of care for DMD. Later this year, the investigational compound will advance into a Phase II trial conducted at centres in the US and Europe to explore its potential further. Read our press release to learn more about the unmet needs in DMD and how we strive to address them: https://bit.ly/4vexht3 #DMD #Duchenne #ClinicalDevelopment #WeAreGrünenthal